Anamorelin Reference

Plain English

What it is

Anamorelin is a man-made compound taken by mouth that acts like ghrelin, the body's natural hunger hormone. By switching on the ghrelin receptor it raises appetite and nudges the body to make more growth hormone and IGF-1 (a growth signal). It is NOT FDA-approved in the United States. It is approved only in Japan, where it is sold as Adlumiz to treat the appetite loss and muscle and weight wasting (called cancer cachexia) that can come with certain cancers.

What people use it for

In Japan it is a prescription medicine for the appetite loss and muscle wasting seen with some cancers. Online, some people in the growth-hormone community talk about it as a pill-form alternative for stimulating the growth-hormone axis without injections. That body-composition use reaches well beyond the cancer setting it was actually studied and approved for.

What the science shows

Large late-stage human trials in cancer patients found it can raise lean body mass and appetite, but it did not clearly improve grip strength or quality of life. European regulators turned it down for that reason. Evidence in healthy people or for looks and body composition is thin to nonexistent.

The catch

It is not approved in the US for any use, so there is no FDA label and no US safety oversight. European regulators rejected it because the benefit looked marginal. Using it outside cancer care runs ahead of the evidence. For research and educational purposes only. Not medical advice.

Reference summary

Phase 3 trial data in cancer cachexia have been published. pepSmart displays anamorelin as trial-context plus non-US-approval educational content; US framing is investigational only.

Regulatory and posture

Categories

GH Release, Fat Loss

Aliases

Adlumiz (Japan), ONO-7643, Oral ghrelin agonist

Evidence posture

human - Approved in Japan (Adlumiz) for cancer cachexia, not FDA-approved in the US. Community body-composition framing extrapolates beyond the approved oncology indication.

Regulatory status

Investigational in the United States. Anamorelin is approved in Japan for cancer cachexia under the brand Adlumiz. There is no FDA-approved US drug label, and US use is not approved for any indication.

Content review status

investigational verified

Related tools

• Protocol builder overview - Public overview of the Pro protocol builder.